The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 medicines defect information drug alert for Bleo-Kyowa, Powder for Solution Injection. Kyowa Kirin is advising caution in use for a specified batch of Bleo-Kyowa, Powder for Solution for Injection, 15,000IU (bleomycin sulfate) following the detection of glass particles.
Further details of the alert, the affected batch, and action to take are available on the MHRA website.